New York State Common Retirement Fund Has $6.57 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

New York State Common Retirement Fund trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 273,651 shares of the biotechnology company’s stock after selling 18,995 shares during the quarter. New York State Common Retirement Fund’s holdings in Exelixis were worth $6,565,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of EXEL. California Public Employees Retirement System increased its stake in Exelixis by 11.5% during the 4th quarter. California Public Employees Retirement System now owns 1,974,291 shares of the biotechnology company’s stock valued at $47,363,000 after purchasing an additional 203,163 shares in the last quarter. RWA Wealth Partners LLC acquired a new position in shares of Exelixis during the fourth quarter valued at about $240,000. Jennison Associates LLC increased its position in shares of Exelixis by 0.5% during the fourth quarter. Jennison Associates LLC now owns 164,200 shares of the biotechnology company’s stock worth $3,939,000 after acquiring an additional 815 shares in the last quarter. Hussman Strategic Advisors Inc. raised its holdings in shares of Exelixis by 13.1% in the 4th quarter. Hussman Strategic Advisors Inc. now owns 147,000 shares of the biotechnology company’s stock worth $3,527,000 after acquiring an additional 17,000 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Exelixis by 16.7% in the 4th quarter. Handelsbanken Fonder AB now owns 64,366 shares of the biotechnology company’s stock valued at $1,544,000 after acquiring an additional 9,200 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Down 1.0 %

NASDAQ EXEL opened at $21.90 on Friday. The firm has a market cap of $6.38 billion, a P/E ratio of 34.22, a price-to-earnings-growth ratio of 0.57 and a beta of 0.57. The company’s 50 day moving average is $22.97 and its 200-day moving average is $22.22. Exelixis, Inc. has a 12-month low of $18.52 and a 12-month high of $24.34.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The company had revenue of $425.23 million during the quarter, compared to the consensus estimate of $461.04 million. During the same period in the previous year, the business earned $0.12 earnings per share. Exelixis’s revenue was up 4.0% on a year-over-year basis. Equities analysts expect that Exelixis, Inc. will post 1.23 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on EXEL shares. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of Exelixis in a research report on Friday. Barclays cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective on the stock. in a research note on Thursday, April 11th. TD Cowen upped their target price on shares of Exelixis from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada raised their price target on shares of Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Six research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and an average target price of $26.33.

Insider Buying and Selling at Exelixis

In other news, Director Alan M. Garber sold 19,205 shares of the stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the sale, the director now directly owns 35,703 shares of the company’s stock, valued at $857,229.03. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Patrick J. Haley sold 47,020 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the completion of the transaction, the executive vice president now directly owns 384,866 shares in the company, valued at $8,255,375.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Alan M. Garber sold 19,205 shares of the firm’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares in the company, valued at approximately $857,229.03. The disclosure for this sale can be found here. Insiders own 2.85% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.